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resource allocation. The objective of this study is to compare the company-predicted 
budget impact with the actual budget impact of high-cost drugs reimbursed in 
Ireland. Methods: All drugs submitted to the health service executive (HSE, health 
care payer in Ireland) for reimbursement under the high-tech drug scheme (a scheme 
used to administer high cost drugs) from 2009 to 2012 were included in the review. 
Company estimates of the likely budget impact of the drug in 2013 were extracted 
from submissions and compared with actual expenditure in 2013 from the health ser-
vice executive-primary care reimbursement service (HSE-PCRS). Only drugs for which 
budget impact estimates were available and which were reimbursed by the HSE in 
2013 were included in the analysis. Results: Ten drugs were included in the analysis, 
including six cancer drugs, two immunomodulators for multiple sclerosis and rheu-
matoid arthritis, and two orphan drugs for cystic fibrosis and idiopathic thrombocyto-
penic purpura. The cumulative expenditure on these drugs in 2013 was € 55.8 million 
compared with a predicted gross budget impact of € 53.4 million, representing a € 2.4 
million underestimate in company submissions. The most significant underestimate 
related to the drug for multiple sclerosis (€ 3.4 million) while the biggest overestimate 
related to the orphan drug for cystic fibrosis (€ 2.9 million). ConClusions: Company 
submissions have been shown to both under- and over-estimate budget impact pre-
dictions. It is important that budget impact estimates are as realistic as possible 
in order to effectively inform decisions on resource allocation or reimbursement.
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objeCtives: The dynamic of the reimbursement politics shows a very differ-
ent pattern in different countries. The REDEL study examined the elapsed time 
from marketing authorization to the starting date of reimbursement of the origi-
nal medicines in Central and Eastern European Countries (Austria, Bulgaria, the 
Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia and 
Slovenia). Methods: The basis of comparison were 216 products and their ATC 
codes selected from the database of the European Medicines Agency which were 
granted a marketing authorization between 1st January 2007 and 1st July 2013. In 
the case of these products the research studied the dates, when countries adopted 
them into their reimbursement system. The adoption was the subject of the study 
between 1st January 2010 and 1st July 2013. The following three different indicators 
were calculated in the study: REDEL - the delay between marketing authorization 
date and reimbursement date; INNREIMB - the number of reimbursed INNs accord-
ing to a specific country or MAH; SR - Success Rate as the ratio of reimbursed 
INNs to examined INNs. Results: While an average of 403 days elapsed between 
the authorization and the starting date of reimbursement in Slovenia (mean of 76 
products), the same period was 1295 days in Poland (mean of 21 adoptions). The 
average is 632 days. The top three in the ranking of REDEL of active substances 
(ATC 1st level – anatomical main group) were dermatologicals (D), respiratory sys-
tem (R) and Muscolo-skeletal system (M). ConClusions: The results show that 
even threefold differences exist among the studied countries with regards to the 
reimbursement delay. An average of almost two years elapse until a producer can 
have the given product adopted into the reimbursement system in a country (the 
REDEL steadily increasing in the studied period, while the number of reimbursed 
products decreasing).
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objeCtives: Price negotiations of a pharmaceutical company with the German 
GKV-Spitzenverband (Association of Statutory Health Insurance) after early ben-
efit assessments can be considered a black box. This analysis aims at providing 
insights on the parameters that drive the final rebate to predict future pricing 
decisions and to enhance the negotiation strategy and therefore secure optimal 
pricing. Methods: Published benefit assessments from the G-BA (Federal Joint 
Committee) website and the products’ prices as listed in the German pharmacy 
selling system were used as a basis for research. The latter allows a comparison of 
launch prices (manufacturer selling prices) and prices after the negotiation with 
the GKV-Spitzenverband (reimbursement prices). The following parameters were 
analyzed: Rebate size, rebate by added benefit rating, and rebate by therapeutic 
area. Results: By June 2014, 36 products had been through price negotiation, with 
the rebate of the launch price ranging from 5-71% (average: 25%). The rebate of prod-
ucts with considerable benefit rating ranged from 10-35% (average: 21%). Products 
with minor added benefit reached rebates between 5-48% averaging at 23%. Products 
with no quantifiable benefit yielded rebates ranging from 11-44% (average: 24%). 
Products with no additional benefit had a rebate between 5-71% averaging at 27%. 
Products in oncology yielded an average rebate of 27%., followed by endocrinology 
(23%), central nervous system (22%), cardiovascular (21%), and infectious diseases 
(16%). ConClusions: The better the added benefit rating of a product, the lower 
is its negotiated rebate. However, only marginal average differences were observed. 
The rebate per therapeutic area did not reveal obvious patterns: Assessments for 
oncology products resulted in above average rebates, while rebates for products for 
infectious diseases were far below the average.
PHP139
comPaRiSon of PoSt-autHoRiSation meaSuReS fRom RegulatoRy 
autHoRitieS WitH additional evidence RequiRementS fRom Hta 
bodieS in geRmany
Ruof J.1, Staab T.R.1, Slawik L.2, Orben T.3, Bosch S.4
1Roche Pharma, Grenzach-Wyhlen, Germany, 2Bristol-Myers Squibb GmbH und Co. KGaA, 
Munich, Germany, 3vfa, Berlin, Germany, 4Bayer Business Service GmbH, Leverkusen, Germany
objeCtives: Regulatory authorities such as the European Medicines Agency 
(EMA) can make marketing authorisation contingent upon post-authorisation 
measures (PAMs) so as to fill in information gaps in efficacy and safety. 
PAMs are generally formulated in agreement with manufacturers, and evalu-
ate clinical hypotheses in an ethical and practical way. In Germany, novel 
medicines must also undergo an early benefit assessment (EBA) by the Federal 
Joint Committee (G-BA) following marketing authorisation. G-BA may demand 
additional evidence in order to formulate an opinion on added therapeutic 
value, which then leads to determination of reimbursement. We compared 
selected PAMs with the corresponding G-BA demands to see if they were sim-
ilar. Methods: Medicines that received a restricted EBA from G-BA before 15 
June 2014 were evaluated and compared with their marketing authorisations by 
EMA. PAMs from EMA, and EBA restrictions from G-BA, were assessed in terms 
of their required additional evidence. Results: Twenty-eight percent of all 79 
medicines assessed by G-BA received a restricted EBA. Only nine of those had 
obligations for PAMs. Four of these were conditional approvals or approval under 
exceptional circumstances, while five received unconditional marketing authori-
sation. G-BA justified restricted EBAs for the four conditional approvals based 
upon agreement with the EMA opinion. For the five unconditional approvals, 
G-BA required considerably more information than EMA. The additional evidence 
requested by the two bodies rarely corresponded to one another. EBA restric-
tions were more influenced by transferability to the German health care context, 
choice of subgroups and appropriate comparator, than were the corresponding 
EMA PAMs. ConClusions: G-BA often demands more evidence than specified 
in EMA PAMs from medicines granted unconditional approval. Although PAMs 
are discussed and agreed between EMA and manufacturers, G-BA demands and 
restrictions are not. The possibility for such discussions with G-BA would be an 
improvement for the future.
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objeCtives: Country-specific lists of standard costs can reduce the variability of 
results in health economic evaluations that are attributed to differences in employed 
data sources and approaches for defining the resource use and unit prices. Moreover 
they potentially speed up the conduct of health economic evaluations. We aim to 
investigate which HTA agency officially recognizes and applies a standard cost list 
and, where such list exists, explore pre-specified procedural and methodological 
aspects. Methods: Reviewing all national pharmacoeconomic guidelines published 
on the ISPOR Website http://www.ispor.org/PEguidelines/index.asp in English (i.e., 30 
out of 37). Standard cost lists mentioned in the guidelines were, inter alia, compared on 
the following aspects: i) objective, ii) authorship, iii) release interval, iv) data sources, 
v) costing perspective, vi) cost categories, and vii) health-state costing. Results: Out 
of the 30 pharmacoeconomic guidelines available in English, a standard cost list was 
officially recognized and applied by 4 HTA agencies (Canada, England, Australia and 
the Netherlands). All 4 lists aim to reduce heterogeneity between health economic 
evaluations in order to increase the comparability. Compiling the standard cost lists 
was commissioned to external scientific institutions in all 4 countries. Updates of the 
lists have been published periodically, spanning from anually (e.g. England) to when 
required for methodological reasons or to ensure currency (e.g. the Netherlands). 
Data collection was primarily based on claims data and/or official statistics; in the 
Netherlands, published research and expert opinions can be employed (for estimating 
resource use). Costs were derived from a payer perspective. Both direct and indirect 
costs were stated, except for Australia (only direct costs). No country presented costs 
in relation to health states. ConClusions: Standard cost lists are mentioned in 
13% of the pharmacoeconomic guidelines available in English. The 4 lists conicide 
on many procedural and methodological aspects. Heterogeneity arises mainly from 
country-specific costs.
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objeCtives: Examine the time between regulatory approval and launch/pricing and 
reimbursement (P&R) approval in the US and EU5 countries.  Methods: Examined 
new molecular entities, formulations and combinations with EMA approval between 
Jan 2009 and May 2014.  Additional analysis of products launched between April 2013 
and May 2014. Time comparison for general medicines vs. orphan/oncology indica-
tions was made including shifts over time.  Data gathered from: USA: FDA approval 
date, wholesale; acquisition cost effective date; UK/Germany: Product availability/
introduction; France: P&R decision (Agrément collectivités/date published in Journal 
Officiel); Italy: First Official Gazette P&R Decree publication; and Spain: Date of 
commercialization. Results: Overall, for launches between Jan 2009 and May 2014, 
the average time from FDA approval to US launch was 6 weeks (oncology 4 weeks; 
orphan drugs 2 weeks). Across the EU5, Germany remains the fastest to market. 
Analysis of new products launched between April 2013 and May 2014 shows time 
to access in Spain has increased vs. the previous 5 years (75 vs. 54 weeks). Limited 
numbers of orphan drugs have completed full Spanish P&R process with 106 weeks 
to launch far exceeding all drugs (75 weeks). Italian average time to complete P&R is 
69 weeks, while average time to be listed in class C-nn, without national reimburse-
ment, is only 18 weeks. UK average time to oncology launch appears short (16 vs. 
20 weeks), however HTA assessments often mean significant access delays. French 
orphan drugs assessment is faster vs. all drugs (46 vs. 50 weeks). ConClusions: 
The time to P&R post-regulatory approval increased ~3 weeks in Italy and ~21 weeks 
in Spain for products launched in the latest year vs. all drugs with EMA approvals 
between Jan 2009 and Dec 2013. 
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objeCtives: The aim of the study is to analyze the burden of chronic diseases 
on public health care expenditures using pharmaceutical data regarding about 2 
million individuals. Methods: Data come from the administrative database of 
the third Belgian health insurance funds. Without explicit diagnoses of diseases 
in the database, chronic diseases are mainly estimated using drugs prescription 
(reimbursed medications only) for a treatment of at least 90 days/year. A multi-
variate linear model based on the OLS method is used to analyse the impact of 
23 chronic diseases on health care expenditures, while controlling for age, sex, 
marital and social status, share of hospital expenditures, residential areas and year 
of death. Results: Monthly average health care costs for people with one or more 
chronic conditions is 6 times greater than the ones without any chronic conditions 
(€ 423 vs. € 71). All chronic diseases (except psoriasis) have a significant impact on 
health care (at 1% level). The last months of life, developing or living with cancer, 
chronic renal failure, rare disease and mental disorder are the factors having the 
greatest impact on monthly reimbursed health care expenditures. All things being 
equal, a person at the end of life costs more than € 2,236 per month to the health 
insurance compared to a person not at the end of life. Respectively this amounts to 
€ 3,557, € 3,008, € 2,042 and € 1,151 for people living with a rare disease, chronic renal 
failure, mental disorder and cancer. ConClusions: Results found in this study 
are similar to those observed in other countries. Our findings show in particular 
that chronic diseases significantly drive health care expenditures. Using secondary 
data allows to classify chronic diseases according to the financial weights while 
controlling for characteristics of the analysed population. Results highlight the high 
financial burden of chronic diseases for public health care expenditures and allow 
decision-makers to take appropriate public health measures.
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objeCtives: China’s medical insurance coverage surpassed 95% nationwide by 2011 
under three basic medical insurance schemes UEBMI, URBMI and NCMS, partly due 
to the government’s heavy investment since 2009. It is still inconclusive whether 
the increased coverage rate has improved access to care. Past studies using the 
China Health and Nutrition Survey (CHNS) focused on data before 2009. This study 
investigates effects of the three different insurance schemes on health services 
utilization after the 2009 new health reform. Methods: An analysis was conducted 
on 2009 and 2011 data from the CHNS (sampling totally 23202 people from 9 prov-
inces). To control for confounding factors, propensity score matching models were 
developed controlling for relevant factors such as age, gender, income, educational 
level and health status. The level difference of health service utilization was com-
pared between each insured and the uninsured group. Attempts were also made to 
compare average treatment costs per episode; however the data set is incomplete 
for statistical analysis. Results: In the matched samples, the UEBMI group on 
average used 2.7% less outpatient services (p< 0.05) but 1.2% more inpatient ser-
vices than the uninsured group (p< 0.05). By contrast, the URBMI group was more 
likely to pay both outpatient and inpatient visits than the uninsured, although both 
improvements were not statistically significant (p> 0.05). People in the NCMS group 
were 5.6% less likely to use outpatient services (p< 0.05); they also tended to use 
inpatient services less (p> 0.05). ConClusions: Access to care across the varying 
schemes is not equal. Differences between the UE/URBMI and the uninsured may 
be resulted from different health statuses, but also they could reflect the tendency 
among the employed to delay care seeking. The relative underutilization of care by 
the rural population points again to high co-payment requirement. More research 
is necessary to understand the interplay of care infrastructure and individual care 
utilization in China.
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objeCtives: To investigate quantitatively, which influence the chosen EU price 
weighting method has in a theoretical framework model of pharmaceuticals price 
negotiations. Methods: Three components theoretically determine the reim-
bursed price of a pharmaceutical under AMNOG conditions in Germany: 1) the 
level and certainty of added benefit, 2) prices of comparable pharmaceuticals 
in Germany and 3) the weighted EU price level (post rebates). In a theoretical 
model the influence of various weighting methods of EU price levels on result-
ing reimbursement was investigated. Results: Several weighting models for EU 
prices are theoretically feasible. When defining the 15 EU basket countries the 
German arbitration board had considered a weighting based on volume, approxi-
mated by country population size and an adjustment by purchasing power parity. 
Operationalisation of each of those factors showed a significant influence on 
results in our simulation: in several example cases a population and PPP health 
basket (Eurostat) was set as base case. Using a weighting based on GDP (in PPP) 
instead, resulted in a ~10-15% increase and based on Eurostat general goods 
basket (in PPP) in a ~20-25% increase in the calculated average EU price level. 
Actual observed EU drug volumes appeared to rather support such cases than 
the weighting based on the Eurostat PPP health basket. Which currency exchange 
rate was used, e.g. yearly vs. daily, Eurostat vs. other sources, had only a minor 
influence in most constellations. The launched country basket showed an overall 
high impact, with a frequently high importance of the U. K. as an EU country being 
launched relatively early. ConClusions: The chosen weighting method of EU 
prices has a high impact on results of EU average price, which is an important 
component of German price negotiations. No undisputed method exists at the 
time of market entry.
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objeCtives: The payer’s perspective is considered after a drug has been 
granted market access and launched. This is often too late as payers may not 
want to reimburse expensive drugs, especially if the current gold standard is 
cost effective compared to alternatives. This is mostly encountered if the drug 
was, during the clinical trials, compared to sub-standard comparators. This 
research aims to establish whether there are interventions to consider during a 
drug development cycle, and how, by using Key Intervention Points, a drug can 
be successful in the market. The first in a series of questions aims to define what 
exactly market access is. Methods: A literature review was conducted on Ovid 
MEDLINE to establish a whether a clear and internationally validated definition 
of market access has been proposed. Included were articles and/or reviews con-
cerning market access of pharmaceuticals for human use published from January 
1999 to present day. Results: Market access can be thought of as either gain-
ing regulatory approval from bodies such as Food and Drug Administration or 
European Medicines Agency to make a drug available to patients, or as develop-
ing a drug that achieves blockbuster status through successful reimbursement, 
either through a high number of sales, or a higher-than-competitor premium 
price. Regulatory approval and reimbursement are often thought of as being inher-
ently different, yet both share the central principle of balancing the benefits and 
harms in deciding availability of drugs. The main difference between regulatory 
approval and reimbursement is the scope of benefits and harm, and the popu-
lation they consider. ConClusions: Market access is difficult to define, with 
different opinions and perspectives. There currently lacks a clear, internationally 
validated method of defining exactly what it market access entails, and what it 
means to have successfully achieved it. There is a need to definitively define this 
important concept.
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objeCtives: This analysis aims at presenting different market access path-
ways of Medical Nutrition (MN) products in the US, France, Germany and the 
UK. Methods: Systematic review of submission processes for MN and food 
for special medical purpose (FSMP), combined with experience of the authors 
from previous research on health economics, Market Access and reimburse-
ment. Results: When considering MN delivered in the ambulatory care setting, 
only in France, innovative MN presenting with therapeutic value faces the medi-
cal device reimbursement process. In the UK, the process is handled by the ACBS 
and focus mainly on clinical outcome and safety; additionally this process sets 
a reimbursed price. In the US and Germany, there are reimbursed categories for 
MN linked to composition of the product and dedicated to patients with inability 
to have their nutritional needs covered by normal food intake (set by CMS in the 
US and G-BA in Germany). Creating new reimbursed categories linked to new 
MN either bringing innovative therapeutic value or targeting new disease area is 
highly difficult in all countries. For MN delivered in hospital settings, products 
delivered enterally or orally are mainly covered by hospital budget. The budget 
can be either from the hospital’s kitchen for thickened and thickening products, 
under the diagnosis-related group funding scheme related to each countries, by 
the nutritionist budget (mainly UK and US) or by the hospital’s pharmacy budget 
for specialties. For standard products, access is obtained based on tenders. In 
long-term care and nursing home, coverage and funding are more heterogene-
ous: they vary from highly regulated reimbursed scheme based on composition of 
the products and disease area to per diem fee per patient covering both food and 
MN. ConClusions: The market access pathways for granting reimbursement 
or coverage of the medical nutrition category are very heterogeneous between 
the analyzed countries.
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objeCtives: Over the past decade increasing numbers of expensive drugs have 
entered the market, placing a financial burden on hospitals in particular. Many 
high-cost therapies require use or at least initiation in the hospital setting. Many 
European countries reimburse hospitals via diagnosis-related group (DRG) systems. 
However, DRG systems are often insufficient to cover the costs of expensive drugs. 
Here we assess how expensive drugs are funded in hospitals across markets, what 
the requirements are, and the process of additional funds being granted. Methods: 
Publicly available documents, governmental guidelines and regulations were 
assessed to understand the different processes and requirements expensive drugs 
need to meet to receive additional funding. Countries included were the UK, France, 
Germany, Italy, Spain, the Netherlands, Sweden, Denmark, Switzerland, Austria and 
Portugal. Results: In all included countries, hospital treatments are reimbursed 
via DRG systems, and most provide additional funding for expensive drugs. There 
